LightRay
Are You Eligible?This trial is testing Sotatercept (MK-7962) in adults with pulmonary arterial hypertension (PAH).
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
PAH is a type of high blood pressure that affects arteries that go from the heart to the lungs. Sotatercept given by weight-based dosing has been approved in the US (but not yet in Australia) to treat PAH in adults. This trial aims to test the safety of Sotatercept and compare 2 different methods of dosing: “weight-based” (dose based on exact body weight) and “weight-banded” (dose based on weight bands with a different dose assigned to each band).
Eligibility
- Age 18 years or over
- Weight >35kg
- Group 1 Pulmonary Artery Hypertension
- On stable therapy for a least 90 days
Lead investigator
- Private: Dr John Feenstra
Clinical trial coordinators
- Chris Henderson
- Marie-Louise Oegema
Technical title
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
The clinical trial is closed for recruitment